Appointment of Bill Pfost brings more than three decades of spine industry experience to support the company's continued growth and broader adoption of minimally invasive endoscopic spine solutions.
elliquence Names Spine Industry Veteran Bill Pfost Chief Executive Officer
3 min read Premium comments
appointmentelliquence LLCBill PfostChief Executive OfficerCFO
BALDWIN, N.Y., Oct. 8, 2026 /PRNewswire-PRWeb/ -- elliquence, LLC, a global leader in minimally invasive surgical technologies, today announced the appointment of Bill Pfost as Chief Executive Officer. A seasoned medical device executive with more than 30 years of experience in the spine industry, he will lead elliquence as the company continues to expand its presence in the U.S. and global markets and advance the adoption of minimally invasive endoscopic approaches to spine care.
Pfost brings extensive commercial and executive leadership experience to elliquence, with a career spanning the development, commercialization and distribution of some of the spine industry's most recognized technologies. Most recently, he served as Chief Revenue Officer of Companion Spine, driving the company's vision as a leader in posterior dynamic stabilization. His previous leadership roles include executive positions at Zimmer Spine, Paradigm Spine, and American Medical Concepts.
"elliquence has spent decades developing the technologies, clinical relationships and expertise to help advance this approach, and I'm excited to build on that foundation, broaden its adoption and lead the company into its next phase of growth." - Bill Pfost - CEO
"Bill brings a rare combination of deep spine industry experience, commercial leadership and an understanding of how innovative technologies gain acceptance among physicians and patients," said Daniel Hui, member of the elliquence Board of Directors. "As elliquence works to broaden awareness and adoption of endoscopic approaches to spine care, his industry knowledge, relationships and perspective on the evolving treatment landscape will be invaluable in guiding the company's next stage of growth."
The appointment comes as elliquence continues to build awareness of minimally invasive endoscopic techniques as an important option across a range of spine conditions and procedures. By enabling physicians to access and treat targeted anatomy with minimal disruption to surrounding healthy tissue, endoscopic interventions may offer appropriately selected patients reduced recovery times and the potential for same-day outpatient treatment. This approach reflects elliquence's longstanding philosophy that, when clinically appropriate, less intervention can deliver meaningful benefits for both physicians and patients.
"Throughout my career, I've seen how advances in minimally invasive techniques can fundamentally change the way physicians approach patient care," said Pfost. "I believe that elliquence is well-positioned to evolve as a leader in the advancement of endoscopic procedures. elliquence has spent decades developing the technologies, clinical relationships and expertise to help advance this approach, and I'm excited to build on that foundation, broaden its adoption and lead the company into its next phase of growth."
Pfost began his career at U.S. Surgical Corporation, where he played a role in driving adoption of laparoscopic cholecystectomy as minimally invasive surgical techniques were transforming general surgery. Over the ensuing three decades, he has held senior sales, marketing and executive leadership positions across the medical device and spine industries and has been involved in the development and distribution of less invasive and interventional technologies.
As CEO, Pfost will provide strategic leadership across elliquence's operations, commercial organization and continued market development, with an emphasis on expanding the understanding of endoscopic spine procedures among physicians and patients and supporting the company's long-term growth.
About elliquence
elliquence, LLC is a leading medical device company based in New York, specializing in advanced minimally invasive surgical technologies. With over 50 years of innovation, elliquence is recognized globally for its Surgi-Max Ultra radiofrequency platform alongside its Trigger-Flex bipolar systems, which provides surgeons with unparalleled precision in soft tissue management and preservation. The company's mission is to partner with the medical community to develop high-quality, cost-effective solutions that enhance patient outcomes while reducing procedural risks and recovery times. elliquence's cutting-edge technologies are widely used in endoscopic spine surgery, orthopedics, neurosurgery, and pain management. Known for pushing the boundaries of surgical innovation, elliquence continues to lead the charge in improving the efficiency and effectiveness of minimally invasive procedures.
For further information, please visit www.elliquence.com.
Media Contact
Scott Truelson, Elliquence, 1 516.277.9016, struelson@elliquence.com, Elliquence.com
SOURCE Elliquence
Author
TH
TJ Halvorson
The De Angelis Group | Orthopedics This Week | MSK Innovations
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
elliquence, LLC appointed Bill Pfost as CEO to drive market expansion and adoption of its minimally invasive endoscopic spine solutions. His three decades of spine industry experience, including commercial leadership at Zimmer Spine and Paradigm Spine, will be crucial for broadening awareness and acceptance. The strategic move aims to capitalize on the potential for reduced recovery times and outpatient treatment, enhancing the company's competitive position in global markets.
- Pfost's appointment leverages extensive commercial and executive leadership to scale elliquence's global market presence.
- The strategy focuses on increasing adoption of endoscopic spine care, potentially impacting reimbursement and patient access through reduced recovery times.
PhD Lens: Clinical and outcomes impact
elliquence appointed Bill Pfost as CEO to advance minimally invasive endoscopic spine solutions. These technologies, including the Surgi-Max Ultra radiofrequency platform and Trigger-Flex bipolar systems, enable precise soft tissue management. The approach aims to access targeted anatomy with minimal disruption, potentially leading to reduced recovery times and enabling same-day outpatient treatment for appropriately selected patients, reflecting a focus on improved patient outcomes.
- Endoscopic interventions minimize tissue disruption, aiming for faster patient recovery and potential for outpatient procedures.
- elliquence's core technologies, Surgi-Max Ultra and Trigger-Flex, provide precision for soft tissue management in spine surgery.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.